Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 16/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675747 | 1.00 | LPAR1 (0.42) | LPAR1LPAR5ADRB3ADRB1LPAR3 | |
| SCHEMBL6682221 | 0.96 | LPAR1 (0.43) | LPAR1LPAR5ADRB3ADRB1LPAR3 | |
| SCHEMBL6682219 | 0.96 | LPAR1 (0.43) | LPAR1LPAR5ADRB3ADRB1LPAR3 | |
| SCHEMBL6680794 | 0.94 | ADRB3 (0.43) | LPAR1LPAR5ADRB3ADRB1LPAR3 | |
| SCHEMBL6680799 | 0.94 | ADRB3 (0.43) | LPAR1LPAR5ADRB3ADRB1LPAR3 | |
| SCHEMBL6801228 | 0.93 | ADRB3 (0.40) | LPAR1LPAR5ADRB3ADRB1KCNH2 | |
| SCHEMBL6801226 | 0.93 | ADRB3 (0.40) | LPAR1LPAR5ADRB3ADRB1KCNH2 | |
| SCHEMBL6805823 | 0.91 | ADRB3 (0.37) | LPAR1LPAR5ADRB3ADRB1KCNH2 | |
| SCHEMBL6676293 | 0.89 | ADRB3 (0.53) | LPAR1LPAR5ADRB3ADRB1 | |
| SCHEMBL6676289 | 0.89 | ADRB3 (0.53) | LPAR1LPAR5ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |